Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials

Diana L. Shuster,Rajeev M. Menon,Bifeng Ding,Amit Khatri,Hong Li,Eric P. Cohen,Melissa Jewett,Daniel E. Cohen,Jiuhong Zha

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials

2019

Diana L. Shuster
Rajeev M. Menon
Bifeng Ding
Amit Khatri
Hong Li
Eric P. Cohen
Melissa Jewett
Daniel E. Cohen
Jiuhong Zha

Purpose To characterize the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, and ribavirin in hepatitis C virus (HCV)-infected patients with chronic kidney disease stage 4 (CKD4) or end-stage renal disease (ESRD), including those on dialysis, in the open-label phase 3 RUBY-I and RUBY-II studies.

Keywords:

Gastroenterology
Ritonavir
Hepatitis C virus
Anesthesia
Dialysis
Medicine
Ombitasvir/paritaprevir/ritonavir
Dasabuvir
Paritaprevir
Ribavirin
Ombitasvir
Internal medicine
Hemodialysis
end stage renal disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations